TY - JOUR
T1 - Perceived sensitivity to pain and responsiveness to non-noxious sensation in substance use disorder
AU - Assayag, Naama
AU - Bonneh, Yoram
AU - Parush, Shula
AU - Mell, Haim
AU - Neeman, Ricky Kaplan
AU - Bar-Shalita, Tami
N1 - Publisher Copyright:
© The Author(s) 2019.
PY - 2020
Y1 - 2020
N2 - Objective. This comparative cross-sectional study aimed to characterize individuals with substance use disorder (SUD) in self-perception of pain sensitivity, experimental auditory aversiveness, and non-noxious sensory responsiveness, as well as examine the associations with SUD. Methods. Therapeutic community (TC) individuals with SUD (N=63, male 88.9%) and healthy controls (N=60, male 86.7%) completed the Pain Sensitivity Questionnaire (PSQ) and the Sensory Responsiveness Questionnaire-Intensity Scale (SRQ-IS), followed by a psychophysical auditory battery, the Battery of Averseness to Sounds (BAS)-Revised. Results. The SUD group scored higher on the PSQ (P<0.0001), BASR aversiveness (P<0.0001), BAS-R-unpleasantness (P<0.0001), and on the aftersensation of auditory aversiveness (P<0.0001) and unpleasantness (P<0.000). Fifty-four percent of the SUD group vs 11.7% of the control group were identified as having sensory modulation dysfunction (SMD; P<0.0001). Logistic regression modeling revealed that the SRQ-IS-Aversive score had a stronger relationship, indicating a 12.6-times odds ratio for SUD (P=0.0002). Finally, a risk score calculated from a linear combination of the logistic regression model parameters is presented based on the PSQ and SRQ. Conclusions. This is the first study to explore sensory and aversive domains using experimental and self-reporting in situ, revealing pain perception alteration that co-occurs with high prevalence of SMD, specifically of the over-responsive type. Findings may be significant in clinical practice for treating pain, and for expanding therapeutic modalities as part of broader rehabilitation in TC and beyond, to better meet personalized therapy.
AB - Objective. This comparative cross-sectional study aimed to characterize individuals with substance use disorder (SUD) in self-perception of pain sensitivity, experimental auditory aversiveness, and non-noxious sensory responsiveness, as well as examine the associations with SUD. Methods. Therapeutic community (TC) individuals with SUD (N=63, male 88.9%) and healthy controls (N=60, male 86.7%) completed the Pain Sensitivity Questionnaire (PSQ) and the Sensory Responsiveness Questionnaire-Intensity Scale (SRQ-IS), followed by a psychophysical auditory battery, the Battery of Averseness to Sounds (BAS)-Revised. Results. The SUD group scored higher on the PSQ (P<0.0001), BASR aversiveness (P<0.0001), BAS-R-unpleasantness (P<0.0001), and on the aftersensation of auditory aversiveness (P<0.0001) and unpleasantness (P<0.000). Fifty-four percent of the SUD group vs 11.7% of the control group were identified as having sensory modulation dysfunction (SMD; P<0.0001). Logistic regression modeling revealed that the SRQ-IS-Aversive score had a stronger relationship, indicating a 12.6-times odds ratio for SUD (P=0.0002). Finally, a risk score calculated from a linear combination of the logistic regression model parameters is presented based on the PSQ and SRQ. Conclusions. This is the first study to explore sensory and aversive domains using experimental and self-reporting in situ, revealing pain perception alteration that co-occurs with high prevalence of SMD, specifically of the over-responsive type. Findings may be significant in clinical practice for treating pain, and for expanding therapeutic modalities as part of broader rehabilitation in TC and beyond, to better meet personalized therapy.
KW - Auditory Aversiveness
KW - Pain Perception
KW - Sensory Modulation Dysfunction
KW - Sensory Overresponsiveness
KW - Substance Use Disorder
UR - http://www.scopus.com/inward/record.url?scp=85090816389&partnerID=8YFLogxK
U2 - 10.1093/pm/pnz292
DO - 10.1093/pm/pnz292
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 31782772
AN - SCOPUS:85090816389
SN - 1526-2375
VL - 21
SP - 1902
EP - 1912
JO - Pain Medicine
JF - Pain Medicine
IS - 9
ER -